Skip to content

Amylyx Pharmaceuticals, Inc. AMLX Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$178K
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$27K-640%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.29M+394%
uniQure logo
uniQureQURE
$242K-93.9%
Biohaven logo
BiohavenBHVN
$837K-70.6%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$43.8M-15.8%
Net income-$41.3M-15.0%
EPS (diluted)-$0.37+11.9%

Balance sheet

See full
Cash & equivalents$229.1M+283%
Total debt$5.6M+307%
Total equity$273.2M+35.6%
Total assets$293.6M+33.7%

Cash flow

See full
Operating cash flow-$36.9M+7.4%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$1.89B+390%

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-63.3%-12.2pp
Debt / equity0.0×
Current ratio17.9×+5.8×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amylyx Pharmaceuticals, Inc.'s other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s other noncash income (expense)?
Amylyx Pharmaceuticals, Inc. (AMLX) reported other noncash income (expense) of -$53K in Q1 2026.
What does other noncash income (expense) mean?
This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.